2012 CTRC-AACR San Antonio Breast Cancer Symposium
Total Page:16
File Type:pdf, Size:1020Kb
December 4–8, 2012 Program Schedule 2012 CTRC-AACR How to Make the Most Out of Being A Cooperative Group Member Kathy D. Miller, Indiana University School of Medicine SAN ANTONIO BREAST CANCER Hope S. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center SYMPOSIUM Making the Transition From Fellowship to Faculty Pepper Jo Schedin, University of Colorado Anschutz Medical Campus PROGRAM SCHEDULE Bryan P. Schneider, Indiana University Melvin and Bren Simon Cancer Center (AT PRESS TIME) Refer to www.sabcs.org for the most current information. Mentoring and Supervising Cathrin Brisken, Ecole Polytechnique Fédérale de Lausanne Room Locations Jason S. Carroll, Cancer Research UK Cambridge Research Institute Exhibit Halls A, B, C & D: Street Level Ballrooms A & B: Street Level Negotiating a Job Offer or Promotion Bridge Hall: Street Level Melissa L. Bondy, Baylor College of Medicine Cancer Center Room 206 A-B: Concourse Level Oral Presentation Skills Laura J. van ‘t Veer, UCSF Helen Diller Family Comprehensive TUESDAY, DECEMBER 4, 2012 Cancer Center Douglas Yee, Masonic Cancer Center, University of Minnesota 8:00 am–7:30 pm REGISTRATION Publication Strategies Bridge Hall Harold J. Burstein, Dana-Farber Cancer Institute Pre-registered attendees can obtain materials. Those who Searching for a Job and Interviewing have not yet registered may do so. Michael T. Lewis, Baylor College of Medicine Cancer Center 12:30 pm–2:00 pm Setting Up and Managing a Laboratory CAREER DEVELOPMENT FORUM: A NETWORKING SESSION FOR Jeffrey M. Rosen, Baylor College of Medicine YOUNG INVESTIGATORS Tenure and Promotion Room 206 A–B Suzanne A.W. Fuqua, Baylor College of Medicine Cancer Center Networking and career development opportunities for early career Sharon H. Giordano, The University of Texas MD Anderson scientists. The session is open to early-career scientists, defined as Cancer Center graduate students, postdoctoral or clinical fellows, or medical students The Path Leading to Clinical Trials and residents, who are registered attendees of the SABCS. Massimo Cristofanilli, Fox Chase Cancer Center Space in the workshop is limited to 200 participants; registrations will be * Topics and mentors are subject to change accepted on a first-come, first-served basis and is free of charge. 2:00 pm–7:30 pm Discussion topics & mentors* EDUCATIONAL SESSIONS Balancing Research and Clinical Practice I Ballrooms A & B and Exhibit Hall D Judy E. Garber, Dana-Farber Cancer Institute Supported by an educational grant from Ann H. Partridge, Dana-Farber Cancer Institute Susan G. Komen for the Cure® Balancing Research and Clinical Practice II An update on advances in the technologies available for translational Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center research. Sessions are to provide people with a better understanding Eric P. Winer, Dana-Farber Cancer Institute of the topics of special current interest they hear using the techniques Careers in Industry described. These presentations also provide researchers with a guide to Steven Shak, Genomic Health, Inc. the techniques they should be considering for their studies. Careers in Industry 2:00 pm–3:30 pm Mika Derynck, Genentech, Inc. The Practical Use of Molecular Profiling Ballroom A Careers in Translational Research Moderator: Peter M. Ravdin, MD, PhD Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center UT Health Science Center San Antonio Grant Writing - Basic/Translational San Antonio, TX Yi Li, Baylor College of Medicine Cancer Center Molecular profiling for in situ carcinoma of the breast Grant Writing - Clinical/Translational Lawrence J. Solin, MD, FACR, FASTRO Virginia F. Borges, University of Colorado Denver Albert Einstein Medical Center Matthew J. Ellis, Washington University Siteman Cancer Center Philadelphia, PA How to Become a Clinical Trialist The practical use of molecular profiling: The view of a John R. Yarnold, The Royal Marsden Hospital medical oncologist Nancy U. Lin, Dana-Farber Cancer Institute Antonio C. Wolff, MD Johns Hopkins Kimmel Cancer Center How to Get the Most Out of Your Fellowship Years Baltimore, MD Ian Elliott Krop, Dana-Farber Cancer Institute Use of genomic tests in routine practice and clinical How to Get the Most Out of Your Fellowship Years research in metastatic breast cancer Rachel Schiff, Baylor College of Medicine Lajos Pusztai, MD, DPhil How to Get the Most Out of Your Predoctoral Experience Yale Cancer Center Rong Li, UT Health Science Center at San Antonio New Haven, CT www.aacrjournals.org 3s Cancer Res; 72(24 Suppl.) December 15, 2012 CTRC-AACR San Antonio Breast Cancer Symposium Biology of Triple-Negative Breast Cancer Risk of second primary breast cancer and other serious late Ballroom B complications issues among survivors of breast cancer Moderator: Nicholas Turner, MD Jonine L. Bernstein, PhD Royal Marsden Hospital Memorial Sloan-Kettering Cancer Center London, UNITED KINGDOM New York, NY New vulnerabilities for TNBC – from genetics to Mammary Cell Lineages and Breast Cancer Subtypes therapeutics Ballroom B Thomas Westbrook, PhD Moderator: Michael T. Lewis, PhD Baylor College of Medicine Baylor College of Medicine Houston, TX Houston, TX Triple negative breast cancer: Subtypes, molecular targets, Primitive normal human mammary cells – the forerunners and therapeutic approaches of malignant populations Jennifer A. Pietenpol, PhD Connie Eaves, PhD Vanderbilt University School of Medicine University of British Columbia Nashville, TN Vancouver, CANADA The clonal and mutational evolution of primary triple Deciphering the cellular hierarchy of the mammary gland negative breast cancers and its implication for breast cancer Samuel Aparicio, PhD Marielle Ousset, PhD University of British Columbia Université Libre de Bruxelles Vancouver, CANADA Bruxelles, BELGIUM Clinical Trial Designs for New Therapies Understanding human cancer with single cell genetics Exhibit Hall D Nicholas E. Navin, PhD Moderator: Susan G. Hilsenbeck, PhD UT MD Anderson Cancer Center Baylor College of Medicine Houston, TX Houston, TX Controversies in the Surgical Management of Breast Cancer Early phase trials - What are they for? Exhibit Hall D Susan G. Hilsenbeck, PhD Moderator: Ismail Jatoi, MD, PhD, FACS Baylor College of Medicine UT Health Science Center San Antonio Houston, TX San Antonio, TX What agents should go into trials? Sentinel node biopsy in breast cancer: Before or after Angela DeMichele, MD, MSCE neoadjuvant chemotherapy University of Pennsylvania Perelman School of Medicine Eleftherios Mamounas, MD Philadelphia, PA Aultman Hospital Canton, OH What endpoints should we use? Clifford A. Hudis, MD Evolving trends in implant breast reconstruction Memorial Sloan-Kettering Cancer Center Andrea L. Pusic, MD, MHS, FRCSC New York, NY Memorial Sloan-Kettering Cancer Center New York, NY Randomized clinical trial designs: Still important Sally Hunsberger, PhD The role of MRI in management of primary breast cancer National Cancer Institute Ismail Jatoi, MD, PhD, FACS Rockville, MD UT Health Science Center San Antonio San Antonio, TX What have we learned? Susan G. Hilsenbeck, PhD 6:00 pm–7:30 pm Baylor College of Medicine Tumor Dormancy and Late Recurrences Houston, TX Ballroom A Moderator: George W. Sledge, Jr, MD 4:00 pm–5:30 pm Indiana University Simon Cancer Center Navigating the Obstacles and Risks of Survivorship Indianapolis, IN Ballroom A Moderator: Susan W. Rafte Mechanisms of breast cancer dormancy and recurrence Pink Ribbons Project Lewis A. Chodosh, MD, PhD Houston, TX Perelman School of Medicine University of Pennsylvania Emerging sexual pharmacology for the breast cancer Philadelphia, PA survivor Michael Krychman, MD Tumor dormancy from an experimental biologist’s The Southern California Center for Sexual Health and Survivorship perspective Newport Beach, CA Ann F. Chambers, PhD London Regional Cancer Program Cognitive changes and breast cancer treatments London, CANADA Patricia A. Ganz, MD University of California, Los Angeles Attacking tumor dormancy in the clinic: How do we design Los Angeles, CA the trials? George W. Sledge, Jr, MD Indiana University Simon Cancer Center Indianapolis, IN Cancer Res; 72(24 Suppl.) December 15, 2012 4s Cancer Research December 4–8, 2012 Program Schedule Inflammation and Breast Cancer 8:30 am–11:15 am Ballroom B GENERAL SESSION 1 Moderator: Charlotte Kuperwasser, PhD Exhibit Hall D Tufts University School of Medicine Moderator: Kathy S. Albain, MD, FACP Boston, MA Loyola University Chicago Stritch School of Medicine Mechanism-based insights into prognosis and treatment Maywood, IL of breast cancer derived from high resolution multiphoton 8:30 S1-1. Relative effectiveness of letrozole compared with tamoxifen imaging for patients with lobular carcinoma in the BIG 1-98 trial John Condeelis, PhD Metzger O, Giobbie-Hurder A, Mallon E, Viale G, Winer E, Thürlimann B, Albert Einstein College of Medicine Gelber RD, Colleoni M, Ejlertsen B, Bonnefoi H, Coates AS, Goldhirsch A, Bronx, NY Gusterson B. BIG 1-98 Collaborative Group, International Breast Cancer Breast cancer stroma: a predictor of clinical outcome and Study Group. tumour heterogeneity 8:45 S1-2. ATLAS – 10 v 5 years of adjuvant tamoxifen (TAM) in ER+ Morag Park, PhD disease: Effects on outcome in the first and in the second decade McGill University after diagnosis Montreal, CANADA Davies C, Pan H, Godwin J, Gray R, Peto R, on Behalf of ATLAS Links between inflammation, breast cancer and obesity Collaborators Worldwide. University of Oxford, Oxford, United Kingdom; Charlotte Kuperwasser,